392 related articles for article (PubMed ID: 25446664)
1. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits the development and metastasis of ovarian cancer.
Wu B; Li S; Sheng L; Zhu J; Gu L; Shen H; La D; Hambly BD; Bao S; Di W
Oncol Rep; 2012 Sep; 28(3):903-8. PubMed ID: 22752027
[TBL] [Abstract][Full Text] [Related]
3. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
4. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
5. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
8. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
9. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
11. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Sreekanth CN; Bava SV; Sreekumar E; Anto RJ
Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920
[TBL] [Abstract][Full Text] [Related]
12. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
13. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
14. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
16. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction.
Al-Wahab Z; Mert I; Tebbe C; Chhina J; Hijaz M; Morris RT; Ali-Fehmi R; Giri S; Munkarah AR; Rattan R
Oncotarget; 2015 May; 6(13):10908-23. PubMed ID: 25895126
[TBL] [Abstract][Full Text] [Related]
17. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
18. Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.
Tan XL; Bhattacharyya KK; Dutta SK; Bamlet WR; Rabe KG; Wang E; Smyrk TC; Oberg AL; Petersen GM; Mukhopadhyay D
Pancreas; 2015 May; 44(4):636-47. PubMed ID: 25875801
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
